Related Experiment Video
Updated: May 15, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Acquired factor XIII deficiency: a therapeutic challenge
Françoise Boehlen1, Alessandro Casini, Carlo Chizzolini
1Division of Angiology and Haemostasis, University Hospitals of Geneva and Faculty of Medicine of Geneva, 1211 Geneva 14, Switzerland.
Acquired Factor XIII (FXIII) deficiency with inhibitors presents significant therapeutic challenges. This case highlights a patient with massive bleeding and a persistent FXIII inhibitor despite aggressive treatments, yet achieved clinical stability.
Area of Science:
- Hematology
- Immunology
- Internal Medicine
Background:
- Acquired Factor XIII (FXIII) deficiency is rare, with fewer than 60 reported cases.
- These deficiencies often present with unique clinical manifestations.
- FXIII inhibitors pose significant therapeutic challenges.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management

